People · Operator

Peter F. Longo

Named in public records as an officer, director or promoter · active 2016–2017 · Biotechnology

1
Companies
5
Filings
$14.1M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Aeromics, Inc.BiotechnologySeries A$14.1M$340.3M2016
Operator network

Peter F. Longo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Christine F. Antalik · 1 companies · 1 sharedChristine F. Anta…Frederick F. Jones · 1 companies · 1 sharedFrederick F. JonesGeorge F. Farr · 1 companies · 1 sharedGeorge F. FarrJeff F. Draime · 1 companies · 1 sharedJeff F. DraimeJeffrey F. Draime · 1 companies · 1 sharedJeffrey F. DraimeJohn F. Foster · 1 companies · 1 sharedJohn F. FosterMarc F. Pelletier · 1 companies · 1 sharedMarc F. PelletierMarc Pelletier · 1 companies · 1 sharedMarc PelletierMark F. Day · 1 companies · 1 sharedMark F. DayPaul F. McGuirk · 1 companies · 1 sharedPaul F. McGuirkPaul F. Schlather · 1 companies · 1 sharedPaul F. SchlatherThomas F. Zindrick · 1 companies · 1 sharedThomas F. ZindrickWalter Boron · 1 companies · 1 sharedWalter BoronWalter F. Boron · 1 companies · 1 sharedWalter F. BoronAeromics, Inc. · $14.1M raisedAeromics, Inc.Peter F. LongoPL
Peter F. Longo Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Peter F. Longo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Walter Boron11
Marc Pelletier11
Frederick F. Jones11
Paul F. McGuirk11
Walter F. Boron11
George F. Farr11
Marc F. Pelletier11
John F. Foster11
Jeffrey F. Draime11
Mark F. Day11
Thomas F. Zindrick11
Christine F. Antalik11
Paul F. Schlather11
Jeff F. Draime11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.